Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that low-level laser therapy significantly increased hair growth in women with androgenic alopecia, achieving a 37% greater increase in hair counts compared to placebo.

This review discusses recent data on the use of anabolic-androgenic steroids and other steroid compounds and reports no new clinical results.

This review examines menopause's endocrinology, treatment history, and associated changes, noting key issues for midwife management but reports no new clinical results.

This study found that hair products commonly used by Black women exhibited hormonal activity, which could impact health outcomes and contribute to health disparities.

This review found that platelet-rich plasma therapy improved hair growth and thickness in most studies on alopecia, with the highest improvement seen when combined with Minoxidil.

This paper reviews seven major systemic causes of hair loss and provides a clinical evaluation framework but reports no new experimental results.

This study found that low-intensity light therapy improved quality of life related to emotional, psychosocial, and symptom domains in individuals with androgenic alopecia, with a greater impact observed in women.

This review discusses the role of androgen therapy and neurosteroids in cerebrovascular health, highlighting the potential risks and benefits and the importance of pharmacogenetic testing, but reports no new experimental results.

This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.

In a laboratory study, researchers found that a novel Bioactive Crosslink Repair Complex improved both the protection and repair of chemically damaged hair, enhancing tensile strength, shine, and cuticle alignment when added to bleaching mixtures and leave-in conditioners.

This study utilized the USFDA AERS to identify significant associations between various medications—such as anti-osteoporotic drugs and phenytoin—and gingival disorders, noting emergent signals with finasteride, COVID-19 vaccine, and levothyroxine, suggesting a need for awareness of oral side effects.

This study reported that the Computational Analysis of Novel Drug Opportunities platform effectively uses integrated biological data, including side effects and pathways, to generate potential drug candidates for colon cancer and migraine disorders.

This review discusses recent advances in protein immobilization on bacterial cellulose for various biomedical uses and reports no new clinical results.

This review highlights the potential of microalgae as sustainable sources for nutraceuticals and cosmeceuticals, emphasizing their applications in functional foods, dietary supplements, and cosmetics for roles such as anti-aging and photoprotection in alignment with sustainability principles.

In this study, intradermal injections of extracellular vesicles over six months were reported to be safe and effective in improving hair growth among patients with pattern hair loss, with favorable response linked to specific patient factors and treatment volumes.

This review examines the FDA's 510(k) approval process for low-level laser therapy devices used in treating androgenetic alopecia and reports no new clinical findings.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

A new acne cream effectively reduced acne in trials and awaits FDA approval.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

This article reviews 27 small-molecule drugs approved by the FDA in 2024, noting that among them, eight "first-in-class" drugs with breakthrough therapy status show distinct mechanisms and substantial efficacy improvements in various conditions like cancer and chronic diseases.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.